Structure-guided design and evaluation of oxazolone-based PIM-1 kinase inhibitors with promising anticancer activity

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Pharmacology

Background:

• PIM-1 kinase is a key regulator of cell proliferation and survival, making it a significant target for anticancer drug development.
• Oxazolone derivatives represent a promising scaffold for designing novel kinase inhibitors.

Purpose of the Study:

• To design and synthesize novel oxazolone derivatives as potential inhibitors of PIM-1 kinase.
• To evaluate the inhibitory potential and binding characteristics of selected oxazolone derivatives against PIM-1.
• To assess the anticancer efficacy of the most promising derivative in a human prostate cancer cell line.

Main Methods:

• Structure-guided drug design and molecular docking were employed to identify potential PIM-1 inhibitors.
• Biochemical assays (enzyme inhibition) and biophysical techniques (fluorescence quenching, ITC) were used to characterize inhibitor-PIM-1 interactions.
• Cell proliferation assays were conducted on a human prostate cancer cell line to determine anticancer activity.

Main Results:

• Thirty oxazolone derivatives exhibited favorable binding profiles through molecular docking.
• Synthetic derivatives O20, O23, and O29 showed low-micromolar PIM-1 inhibition (IC50 range: 12-15 µM).
• Compound O29 demonstrated high-affinity binding (Kd in 10^5-10^6 M^-1) and significant anticancer activity (IC50: 8.46 µM) in prostate cancer cells.

Conclusions:

• Oxazolone derivatives, particularly O29, are effective PIM-1 inhibitors with high binding affinity.
• Compound O29 exhibits promising anticancer potential, warranting further investigation for prostate cancer treatment.
• Oxazolone-based scaffolds show potential as lead compounds for developing novel PIM-1 targeted therapies.